SLN360

DRUG2 trials

Sponsors

Silence Therapeutics plc

Conditions

AtherosclerosisCardiovascular DiseasesDyslipidemiasElevated Lp(a)HyperlipidemiasLipoprotein(a)

Phase 1

Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)

CompletedNCT04606602

Silence Therapeutics plcDyslipidemias, Elevated Lp(a), Hyperlipidemias

Start: 2020-11-18End: 2023-08-23Updated: 2024-08-12

Phase 2

Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

CompletedNCT05537571

Silence Therapeutics plcAtherosclerosis, Cardiovascular Diseases, Lipoprotein(a)

Start: 2022-12-13End: 2024-07-01Updated: 2025-07-01

Related Papers

Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

JAMA2024-11-1876 citations

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)

JAMA2024-04-0860 citations

Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels

JAMA2022-04-03266 citations